Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine

Psychopharmacology

Volumn 155, Issue 4, 2001, Pages 338-347

  Nann Vernotica, Ellen ^b   Donny, E C ^a   Bigelow, G E ^a   Walsh, S L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiovascular; Cocaine; Dopamine; Nicotine; Pharmacotherapy; Smoking

Indexed keywords

COCAINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; ECOPIPAM; UNCLASSIFIED DRUG; BENZAZEPINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; DRD5 PROTEIN, HUMAN;

ADULT; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; CROSSOVER PROCEDURE; DRUG ANTAGONISM; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SMOKING; SMOKING CESSATION;

ADULT; BENZAZEPINES; COCAINE; COCAINE-RELATED DISORDERS; CROSS-OVER STUDIES; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; QUESTIONNAIRES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; SMOKING; SMOKING CESSATION;

EID: 0034743920     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130100724     Document Type: Article

References (49)

1. 2 antagonists
2. Evaluation of potential pharmacotherapies: Response to cocaine challenge in the human laboratory
3. 2 receptor antagonists differentially affect cocaine-induced locomotor hyperactivity in the mouse
4. Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat
5. 3 receptor test in vitro predicts decreased cocaine self-administration in rats
6. 2-like agonists in rats that self-administer cocaine
7. 2) on the demand for smoked cocaine base in rhesus monkeys
8. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists
9. Selective dopamine antagonists reduce nicotine self-administration
10. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390
11. Differential effects of response-contingent and response-independent nicotine in rats
12. Response-dependent versus response-independent presentation of cocaine: Differences in the lethal effects of the drug
13. Double-blind comparison of bromocriptine and placebo in cocaine withdrawal
14. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment
15. Measuring nicotine dependence: A review of the Fagerstrom tolerance questionnaire
16. 1 receptor agonists by squirrel monkeys
17. Bromocriptine for cocaine dependence. A controlled clinical trial
18. Effects of pergolide on intravenous cocaine self-administration in men and women
19. 1 agonist (ABT-431) on smoked cocaine self-administration in humans
20. 1 antagonist, on smoked cocaine self-administration by humans
21. Effects of chronic SCH 23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: Potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor up-regulation
22. Enhanced sensitivity to the behavioral effects of cocaine after chronic administration of D2 selective dopamine antagonists in the squirrel monkey
23. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
24. 1 dopaminergic antagonists and agonists in mice and squirrel monkeys
25. Effects of continuous infusions of SCH 23390 on cocaine- and food-maintained behavior in rhesus monkeys
26. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure
27. Interactions between chronic haloperidol treatment and cocaine in rats: An animal model of intermittent cocaine use in neuroleptic-treated populations
28. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence
29. Physiological, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man
30. An automated version of the digit symbol substitution test (DSST)
31. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures
32. 2 receptor activation in the canine cardiac sympathetic ganglia
33. 3 receptor agonist
34. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers
35. Comparison of triazolam and pentobarbital: Performance impairment, subjective effects, and abuse liability
36. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)
37. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medications development. Focus on GBR 12909
38. The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats
39. Effects of intravenous cocaine are partially attenuated by haloperidol
40. Molecular biology of dopamine receptors
41. Molecular neurobiology of dopaminergic receptors
42. Differential modulation of behavioral effects of cocaine by low- and high-efficacy agonists
43. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior
44. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes
45. Cocaine stimulated the human cardiovascular system via a central mechanism of action
46. The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys
47. Preclinical evaluation of pharmacotherapies for cocaine abuse